When Competing Trials Start Eating Your Enrollment
Not every enrollment slowdown is a site problem. Sometimes it's a portfolio problem. Here's how to tell the difference and what to do about it.
Latest
Turning Pain Into Progress
How Sonia Prashar Built a Mission Around Mental Health
Enrollment Slipped Last Week. You'll Find Out Next Month
Your local call center knows exactly how every agent performed today. Your clinical trial sites? They're still filling out spreadsheets.
Why a Tenured Stanford Professor Walked Away to Build What Academia Couldn't
"The last paragraph in a paper is often what you really want to be doing,"
Two Decades, Two ALS Programs, One Key Insight
In 1996, a young psychiatrist named Joseph Palumbo joined Cephalon to work on myotrophin, a promising ALS candidate. It didn't succeed. What he learned shaped the first ALS approval in over 20 years.
Your Best Sites Have Already Solved Your Patient Recruitment Problem
How "positive deviance" can help you find what's working and scale it
Power's 2025 Recap: What 10x Enrollment Growth Taught Us
The operational insights behind our biggest year in patient recruitment
Science Saved It, Execution Proved It: Schizophrenia's First New Mechanism in 70 Years
How a time-constrained 6-month proof-of-concept study and disciplined trial methodology transformed a shelved compound into a $14 billion breakthrough
The Silent Dropout: What Happens After Patients Call? 1K+ Survey Responses Tell the Story
Why patients who seem "engaged" disappear... and what site behaviors may be driving them away
When Engineering Meets Research Legacy: Inside the AtaiBeckley Merger
The AtaiBeckley merger reflects a bet that shorter treatment durations will improve patient access and payer acceptance.
From Telecom to THC: How an Engineer Tackled Alzheimer's Agitation
An engineer's path from NASDAQ IPO to hemp-derived THC trials reveals the operational realities many clin ops teams don't discuss.
The Clinical Execution Playbook Behind Schizophrenia's First New Mechanism
How Karuna's former CMO turned disciplined trial methodology into a $14 billion BMS acquisition
Your Sites Are Losing Patients on Phone Screens (And You'd Never Know)
Why the gap between 'interested patient' and 'scheduled screening' is costing you enrollment
The Alzheimer's Hypothesis Big Pharma Missed
Why a former Genentech director bet on cortisol over amyloid, and what pilot data showing 5x better efficacy could mean for patients